Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc Fornecker

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Haematologica|August 2, 2013
Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplantEric Van Den Neste, Olivier Casasnovas, Marc André, et al.
Transfusion|May 9, 2012
Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patientsFrançois Lefrère, Dominique Bastit-Barrau, Olivier Hequet, et al.
Blood|March 9, 2017
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphomaCharles Herbaux, Jordan Gauthier, Pauline Brice, et al.
Blood|February 11, 2012
Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS studyBruno Lioure, Marie C Béné, Arnaud Pigneux, et al.
Gynecologie, Obstetrique, Fertilite & Senologie|December 17, 2021
[Non-genetic indications for risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)]Carole Mathelin, Emmanuel Barranger, Martine Boisserie-Lacroix, et al.
Blood|November 19, 2020
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSASteven Le Gouill, Hervé Ghesquières, Lucie Oberic, et al.
Cancer Medicine|December 9, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapyLouise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Haematologica|August 2, 2013
Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplantEric Van Den Neste, Olivier Casasnovas, Marc André, et al.
Transfusion|May 9, 2012
Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patientsFrançois Lefrère, Dominique Bastit-Barrau, Olivier Hequet, et al.
Blood|March 9, 2017
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphomaCharles Herbaux, Jordan Gauthier, Pauline Brice, et al.
Blood|February 11, 2012
Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS studyBruno Lioure, Marie C Béné, Arnaud Pigneux, et al.
Gynecologie, Obstetrique, Fertilite & Senologie|December 17, 2021
[Non-genetic indications for risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)]Carole Mathelin, Emmanuel Barranger, Martine Boisserie-Lacroix, et al.
Blood|November 19, 2020
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSASteven Le Gouill, Hervé Ghesquières, Lucie Oberic, et al.
Cancer Medicine|December 9, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapyLouise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, et al.
Pageof 2